The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double‐blind placebo‐controlled study
Abstract
Summary: Background : Ciprofloxacin is effective in perianal Crohn's disease but after treatment discontinuation symptoms reoccur. Infliximab is effective but requires maintenance therapy. Aim : To evaluate the effect of combined ciprofloxacin and infliximab in perianal Crohn's disease. Methods : A double‐blind placebo‐controlled study was conducted. Patients were randomly assigned to receive 500‐mg ciprofloxacin twice daily or a placebo for 12 weeks. All patients received 5‐mg/kg infliximab in week 6, 8 and 12 and were followed for 18 weeks. Primary end‐point was clinical response, defined as a 50% or greater reduction from baseline in the number of draining fistulae. Secondary end‐points were the change in Perianal Disease Activity Index and hydrogen peroxide enhanced three‐dimensional endoanal ultrasonography findings. Analysis was by intention‐to‐treat. Results : Twenty‐four patients were included but two discontinued treatment. At week 18, response was 73% (eight of 11) in the ciprofloxacin group and 39% (five of 13) in the placebo group (P = 0.12). Using logistic regression analysis patients treated with ciprofloxacin tended to respond better (OR = 2.37, CI: 0.94–5.98, P = 0.07). The Perianal Disease Activity Index score only improved (P = 0.008) in the ciprofloxacin group. Three‐dimensional endoanal ultrasonography improved in three patients with a clinical response. Conclusions : A combination of ciprofloxacin and infliximab tended to be more effective than infliximab alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
A classification of fistula-in-ano
Parks, A. G., Gordon, P. H., & Hardcastle, J. D. (1976) · Journal of British Surgery · doi:10.1002/bjs.1800630102 · Cited by 1,663
AGA technical review on perianal Crohn’s disease
Sandborn, W. J., Fazio, V. W., Feagan, B. G., & Hanauer, S. B. (2003) · Gastroenterology · doi:10.1016/j.gastro.2003.08.025 · Cited by 704
Sandborn, W. J., Feagan, B. G., Hanauer, S. B., Lochs, H., Löfberg, R., Modigliani, R., Present, D. H., Rutgeerts, P., Schölmerich, J., Stange, E. F., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.31072 · Cited by 686
Metronidazole Therapy for Perineal Crohn's Disease: A Follow-Up Study
Brandt, L. J., Bernstein, L. H., Boley, S. J., & Frank, M. S. (1982) · Gastroenterology · doi:10.1016/s0016-5085(82)80332-6 · Cited by 468
Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease
Van Assche, G. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05909-9 · Cited by 457
Healing of perineal Crohn's disease with metronidazole
Bernstein, L. H., Frank, M. S., Brandt, L. J., & Boley, S. J. (1980) · Gastroenterology · doi:10.1016/0016-5085(80)90155-9 · Cited by 440
Biologic therapy of inflammatory bowel disease
Sandborn, W. J., & Targan, S. R. (2002) · Gastroenterology · doi:10.1053/gast.2002.33426 · Cited by 344
Usual Therapy Improves Perianal Crohn??s Disease as Measured by a New Disease Activity Index
&NA;, &. (1995) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199501000-00008 · Cited by 322
Cited by
ACG Clinical Guideline: Management of Crohn's Disease in Adults
Lichtenstein, G. R., Loftus, E. V., Isaacs, K. L., Regueiro, M. D., Gerson, L. B., & Sands, B. E. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2018.27 · Cited by 1,421
Antibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis
Khan, K. J., Ullman, T. A., Ford, A. C., Abreu, M. T., Abadir, A., Marshall, J. K., Talley, N. J., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.72 · Cited by 569
D'Haens, G. R., Panaccione, R., Higgins, P. D. R., Vermeire, S., Gassull, M., Chowers, Y., Hanauer, S. B., Herfarth, H., Hommes, D. W., Kamm, M., et al. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.392 · Cited by 409
Molendijk, I., Bonsing, B. A., Roelofs, H., Peeters, K. C. M. J., Wasser, M. N. J. M., Dijkstra, G., van der Woude, C. J., Duijvestein, M., Veenendaal, R. A., Zwaginga, J.-J., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.06.014 · Cited by 329
Self-citationAn Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
Talley, N. J., Abreu, M. T., Achkar, J.-P., Bernstein, C. N., Dubinsky, M. C., Hanauer, S. B., Kane, S. V., Sandborn, W. J., Ullman, T. A., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.58 · Cited by 310
Metadata
- Authors
- West, R. L., van der Woude, C. J., Hansen, B. E., Felt‐Bersma, R. J. F., van Tilburg, A. J. P., Drapers, J. A. G., & Kuipers, E. J.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2004-12
- Volume
- 20
- Issue
- 11-12
- Pages
- 1329-1336
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2063518063
- Cited by
- 256
- References
- 23
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double‐blind placebo‐controlled study. https://app.cochat.ai/papers/10.1111/j.1365-2036.2004.02247.x
- The paper
- West, R. L., van der Woude, C. J., Hansen, B. E., Felt‐Bersma, R. J. F., van Tilburg, A. J. P., Drapers, J. A. G., & Kuipers, E. J. (2004). Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double‐blind placebo‐controlled study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2004.02247.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.